Literature DB >> 21833523

"Mutation negative" familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies.

C M Hedrich1, N Bruck, D Paul, G Hahn, M Gahr, A Rösen-Wolff.   

Abstract

Cryopyrinopathies are a subgroup of autoinflammatory syndromes. Most cases have mutations in the CIAS1/NLRL3 gene, encoding the cryopyrin/NLRP3 protein. Cryopyrin, together with other proteins, is involved in the assembly of the cryopyrin/NLRP3 inflammasome. Mutations in CIAS1/NLRP3 result in increased IL-1β cleavage from biologically inactive pro-IL-1β. This results in systemic inflammation and three associated disorders of different severity, forming a clinical continuum with overlapping features. The mildest from, familial cold autoinflammatory syndrome (FCAS), is characterized by remitting fevers, urticaria-like rash, polyarthralgia/arthritis, and usually caused by cold exposure. More severe forms are Muckle-Wells syndrome (MWS) and CINCA/NOMID. We report an 8-year-old boy with FCAS, who presented with overlapping features with MWS. He showed good response to seasonal anakinra treatment. Mutation analysis in CIAS1/NLRP3, PYCARD, and CASP1 was performed. Serum cytokine profiles, and cytokine expression from resting monocytes, and in response to mild hypothermia, and LPS stimulation were determined. Mutations in CIAS1/NLRP3, PYCARD, and CASP1 were not found. In response to mild hypothermia, an enhanced IL-1β expression by patient monocytes resulted in increased IL-6 and TNF-α secretion, as compared to control cells. The addition of the IL-1β receptor antagonist (anakinra) reversed these effects. In response to LPS stimulation, patient monocytes produced high level of IL-1β, IL-6 and TNF-α. This was markedly less pronounced in control monocytes. FCAS results in cold-induced cytokine dysregulation and systemic inflammation. Symptoms can be treated, using IL-1β antagonists. Further research is warranted, particularly in order to investigate pathophysiological mechanisms in "mutation negative" individuals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833523     DOI: 10.1007/s00296-011-2019-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Hereditary periodic fever syndromes.

Authors:  Daniel L Kastner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

2.  IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA).

Authors:  J C Möller; D Paul; G Ganser; U Range; M Gahr; R Kelsch; A Rösen-Wolff; C M Hedrich
Journal:  Clin Exp Rheumatol       Date:  2011-01-04       Impact factor: 4.473

3.  Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia.

Authors:  Sanna Rosengren; James L Mueller; Justin P Anderson; Brian L Niehaus; Amirhossein Misaghi; Scott Anderson; David L Boyle; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2007-02-22       Impact factor: 10.793

4.  Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations.

Authors:  Marco Gattorno; Sara Tassi; Sonia Carta; Laura Delfino; Francesca Ferlito; Maria Antonietta Pelagatti; Andrea D'Osualdo; Antonella Buoncompagni; Maria Giannina Alpigiani; Maria Alessio; Alberto Martini; Anna Rubartelli
Journal:  Arthritis Rheum       Date:  2007-09

5.  ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions.

Authors:  Anasuya Sarkar; Michelle Duncan; Judy Hart; Erin Hertlein; Denis C Guttridge; Mark D Wewers
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients.

Authors:  Megumu Saito; Ryuta Nishikomori; Naotomo Kambe; Akihiro Fujisawa; Hideaki Tanizaki; Kyoko Takeichi; Tomoyuki Imagawa; Tomoko Iehara; Hidetoshi Takada; Tadashi Matsubayashi; Hiroshi Tanaka; Hisashi Kawashima; Kiyoshi Kawakami; Shinji Kagami; Ikuo Okafuji; Takakazu Yoshioka; Souichi Adachi; Toshio Heike; Yoshiki Miyachi; Tatsutoshi Nakahata
Journal:  Blood       Date:  2007-12-06       Impact factor: 22.113

7.  Analysis of SAA1 gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis.

Authors:  Clio P Mavragani; Nikos Yiannakouris; Elias Zintzaras; Labros Melistas; Kostas Ritis; Fotini N Skopouli
Journal:  Amyloid       Date:  2007-12       Impact factor: 7.141

Review 8.  Rilonacept in the treatment of chronic inflammatory disorders.

Authors:  Michael F McDermott
Journal:  Drugs Today (Barc)       Date:  2009-06       Impact factor: 2.245

9.  Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies.

Authors:  C M Hedrich; B Fiebig; S Sallmann; N Bruck; G Hahn; J Roesler; A Roesen-Wolff; G Heubner; M Gahr
Journal:  Scand J Rheumatol       Date:  2008 Sep-Oct       Impact factor: 3.641

10.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors:  Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

View more
  7 in total

Review 1.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

2.  Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS).

Authors:  M H Haverkamp; E van de Vosse; R Goldbach-Mansky; S M Holland
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 3.  [Caspase-1 regulates autoinflammation in rheumatic diseases].

Authors:  S Winkler; C M Hedrich; A Rösen-Wolff
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

Review 4.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

5.  Neuroprotective effect of interleukin-6 regulation of voltage-gated Na(+) channels of cortical neurons is time- and dose-dependent.

Authors:  Wei Xia; Guo-Yi Peng; Jiang-Tao Sheng; Fang-Fang Zhu; Jing-Fang Guo; Wei-Qiang Chen
Journal:  Neural Regen Res       Date:  2015-04       Impact factor: 5.135

Review 6.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

Review 7.  Infection-Associated Mechanisms of Neuro-Inflammation and Neuro-Immune Crosstalk in Chronic Respiratory Diseases.

Authors:  Belinda Camp; Sabine Stegemann-Koniszewski; Jens Schreiber
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.